Global Elimination of Hepatitis C Virus.

IF 15.1 1区 医学 Q1 MEDICINE, RESEARCH & EXPERIMENTAL Annual review of medicine Pub Date : 2024-11-01 DOI:10.1146/annurev-med-050223-111239
Rachael L Fleurence, Harvey J Alter, Francis S Collins, John W Ward
{"title":"Global Elimination of Hepatitis C Virus.","authors":"Rachael L Fleurence, Harvey J Alter, Francis S Collins, John W Ward","doi":"10.1146/annurev-med-050223-111239","DOIUrl":null,"url":null,"abstract":"<p><p>Hepatitis C virus (HCV) is predominantly transmitted through parenteral exposures to infectious blood or body fluids. In 2019, approximately 58 million people worldwide were still infected with HCV, and 290,000 deaths occurred due to hepatitis C-related conditions, despite hepatitis C being curable. There are substantial barriers to elimination, including the lack of widespread point-of-care diagnostics, cost of treatment, stigma associated with hepatitis C, and challenges in reaching marginalized populations, such as people who inject drugs. The World Health Organization (WHO) has set goals to eliminate hepatitis C by 2030. Several countries, including Australia, Egypt, Georgia, and Rwanda, have made remarkable progress toward hepatitis C elimination. In the United States, the Biden-Harris administration recently issued a plan for the national elimination of hepatitis C. Global progress has been uneven, however, and will need to accelerate considerably to reach the WHO's 2030 goals. Nevertheless, the global elimination of hepatitis C is within reach and should remain a high public health priority.</p>","PeriodicalId":8056,"journal":{"name":"Annual review of medicine","volume":" ","pages":""},"PeriodicalIF":15.1000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annual review of medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1146/annurev-med-050223-111239","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

Abstract

Hepatitis C virus (HCV) is predominantly transmitted through parenteral exposures to infectious blood or body fluids. In 2019, approximately 58 million people worldwide were still infected with HCV, and 290,000 deaths occurred due to hepatitis C-related conditions, despite hepatitis C being curable. There are substantial barriers to elimination, including the lack of widespread point-of-care diagnostics, cost of treatment, stigma associated with hepatitis C, and challenges in reaching marginalized populations, such as people who inject drugs. The World Health Organization (WHO) has set goals to eliminate hepatitis C by 2030. Several countries, including Australia, Egypt, Georgia, and Rwanda, have made remarkable progress toward hepatitis C elimination. In the United States, the Biden-Harris administration recently issued a plan for the national elimination of hepatitis C. Global progress has been uneven, however, and will need to accelerate considerably to reach the WHO's 2030 goals. Nevertheless, the global elimination of hepatitis C is within reach and should remain a high public health priority.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
全球消除丙型肝炎病毒。
丙型肝炎病毒(HCV)主要通过肠外接触传染性血液或体液传播。尽管丙型肝炎可以治愈,但2019年全球仍有约5800万人感染了丙型肝炎病毒,29万人死于丙型肝炎相关疾病。消除丙型肝炎存在巨大障碍,包括缺乏广泛的护理点诊断、治疗成本、与丙型肝炎相关的耻辱感,以及在覆盖边缘化人群(如注射毒品者)方面的挑战。世界卫生组织(WHO)制定了到 2030 年消除丙型肝炎的目标。包括澳大利亚、埃及、格鲁吉亚和卢旺达在内的一些国家在消除丙型肝炎方面取得了显著进展。在美国,拜登-哈里斯政府最近发布了一项在全国范围内消除丙型肝炎的计划。然而,全球进展并不均衡,要实现世界卫生组织 2030 年的目标,还需要大大加快步伐。尽管如此,全球消除丙型肝炎仍指日可待,并应继续作为公共卫生的高度优先事项。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Annual review of medicine
Annual review of medicine 医学-医学:内科
CiteScore
24.90
自引率
0.00%
发文量
58
期刊介绍: The Annual Review of Medicine, which has been published since 1950, focuses on important advancements in diverse areas of medicine. These include AIDS/HIV, cardiology, clinical pharmacology, dermatology, endocrinology/metabolism, gastroenterology, genetics, immunology, infectious disease, neurology, oncology/hematology, pediatrics, psychiatry, pulmonology, reproductive medicine, and surgery. The journal's current volume has transitioned from a gated access model to an open access model through the Annual Reviews' Subscribe to Open program. All articles published in the journal are now available under a CC BY license.
期刊最新文献
Endoscopic Approaches for Managing Small Intestinal Disease. Care Models for Cancer Survivors. Candida auris: Epidemiology and Antifungal Strategy. Application and Expectations for Immune Checkpoint Blockade of LAG3 and TIGIT. New Approaches to Respiratory Syncytial Virus Prevention and Treatment.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1